Ceftolozane/tazobactam in action: Prescribing patterns, effectiveness, and healthcare utilisation across seven countries
This multi-national, retrospective, observational study demonstrates the real-world use and healthcare resource utilisation (HCRU) of C/T in patients with Gram-negative infections across seven countries. These findings provide valuable insights into prescribing patterns and resource implications of C/T treatment, underscoring the importance of real-world data to inform clinical practice and optimise antimicrobial therapy in diverse healthcare settings.
Authors
- David L. Paterson (ORCID: https://orcid.org/0000-0003-2079-4437)
- Àlex Soriano (ORCID: https://orcid.org/0000-0002-9374-0811)
- Emre Yücel (ORCID: https://orcid.org/0000-0002-6036-9526)
- Pierluigi Viale (ORCID: https://orcid.org/0000-0003-1264-0008)
- Florian Thalhalmmer
- Stefan Kluge (ORCID: https://orcid.org/0000-0001-8391-3988)
- Brune Akrich
- Sunny Kaul (ORCID: https://orcid.org/0000-0001-6560-054X)
- Mike Allen
- Jessica Levy
- Huina Yang
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Universität Hamburg (DE)
- The University of Queensland (AU)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- Tan Tock Seng Hospital (SG)
- MSD (UK) Limited (United Kingdom) (GB)
- University Medical Center Hamburg-Eppendorf (DE)
- Hospital Clínic de Barcelona (ES)
- Medical University of Vienna (AT)
- University of Bologna (IT)
Publication Details
- Journal
- Journal of Global Antimicrobial Resistance
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1016/j.jgar.2025.10.013
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00